Benzinga · Oct 28, 2026
HC Wainwright & Co. Reiterates Buy on Neurogene, Maintains $65 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Neurogene (NASDAQ:NGNE) with a Buy and maintains $65 price target.
NG
NASDAQ · NGNE
Neurogene Inc.
Healthcare · Biotechnology
$27.55
Down-$1.27 (-4.41%)
Updated Oct 31, 2026, 11:39 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 329.3M
- P/E ratio
- -5.29
- Dividend yield
- 0.00%
- 52-week range
- $18.23 – $43.66
- Volume
- 249.05K
- Avg. volume
- 231.35K
Price performance · NGNE
NGNE price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
NGNE closed at $27.55 after 21 trading sessions, up 7.41% for the selected period.
- Last close
- $27.55
- Period change
- +7.41%
- Period low
- $21.56
- Period high
- $30.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $28.53 | $29.3764 | $26.765 | $27.55 | 249.05K |
| Oct 29, 2026 | $30.50 | $32.09 | $28.50 | $28.82 | 310K |
| Oct 28, 2026 | $26.99 | $31.14 | $25.81 | $30.42 | 646.31K |
| Oct 27, 2026 | $23.71 | $27.225 | $23.26 | $26.99 | 484.95K |
| Oct 26, 2026 | $23.75 | $24.4293 | $23.32 | $23.54 | 123.2K |
| Oct 23, 2026 | $24.11 | $24.11 | $23.075 | $23.55 | 124.51K |
| Oct 22, 2026 | $25.74 | $26.38 | $24.0901 | $24.28 | 212.38K |
| Oct 21, 2026 | $25.52 | $26.94 | $25.105 | $26.08 | 588.81K |
| Oct 20, 2026 | $24.20 | $25.84 | $23.795 | $25.40 | 205.9K |
| Oct 19, 2026 | $23.26 | $24.39 | $22.78 | $24.17 | 240.18K |
| Oct 16, 2026 | $24.00 | $24.27 | $23.00 | $23.25 | 571.53K |
| Oct 15, 2026 | $22.35 | $24.41 | $22.35 | $23.95 | 587.99K |
| Oct 14, 2026 | $21.05 | $22.50 | $21.05 | $22.18 | 522.55K |
| Oct 13, 2026 | $24.32 | $25.1744 | $21.395 | $21.56 | 442.25K |
| Oct 12, 2026 | $26.13 | $27.15 | $24.19 | $24.44 | 388.01K |
| Oct 9, 2026 | $28.90 | $29.63 | $26.01 | $26.40 | 465.9K |
| Oct 8, 2026 | $28.00 | $28.97 | $26.24 | $26.50 | 509.48K |
| Oct 7, 2026 | $25.14 | $26.005 | $25.01 | $25.87 | 114.07K |
| Oct 6, 2026 | $26.63 | $26.74 | $25.04 | $25.45 | 121.65K |
| Oct 5, 2026 | $25.71 | $26.76 | $24.865 | $26.47 | 211.77K |
| Oct 2, 2026 | $26.95 | $26.95 | $24.86 | $25.65 | 401.64K |
Latest NGNE news
The latest Smart Investors Daily articles mentioning NGNE.
Stock researchCompany · Overview
Company
Market Activity
Research & News
NGNE research
Overview
Company profile and research snapshot.
Company profile
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $45.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 28, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 8, 2026 | JP Morgan | Overweight | — |
| Aug 12, 2026 | Canaccord Genuity | Buy | — |
| Aug 12, 2026 | Guggenheim | Buy | — |
| Aug 12, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
NEW YORK, October 27, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, will present data related to its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany. The new preclinical data are expected to further validate NGN-401’s differentiated desig
Benzinga · Oct 27, 2026
Neurogene To Present Data Related To NGN-401 Gene Therapy Program For Rett Syndrome At ESGCT 33rd Annual Congress; New Preclinical Data Expected To Further Validate NGN-401’s Differentiated Design
New data showing rapid and durable full-length MECP2 expression in vivo with single-stranded AAV support improvements observed in NGN-401 Phase 1/2 trialNew in vivo data demonstrate that miRNA-based auto-regulatory
Yahoo · Oct 20, 2026
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
NEW YORK, October 20, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will present data from its NGN-401 gene therapy program for Rett syndrome at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress, taking place October 27-30, 2026, in Hamburg, Germany.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
